文献速递中毒与环境急症消化、代谢与肾脏急症

缓释7日注射用丁丙诺啡用于阿片戒断极轻至轻度患者

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
PubMed 文献 · JAMA Netw Open · 2024-07-01
一句话结论在COWS 0-7的阿片类物质使用障碍急诊患者中,单次24 mg缓释7日丁丙诺啡注射(CAM2038)可接受、耐受良好且安全,COWS 4-7者更优。

这项非随机试验在美国4个急诊科纳入100例年龄≥18岁、中度至重度阿片类物质使用障碍且COWS<8(极轻至轻度戒断)的成人,给予单次24 mg缓释7日丁丙诺啡(CAM2038)注射并转介持续治疗。4小时内COWS升高≥5分者10例(10.0% [95%CI, 4.9%-17.6%]),转为中度及以上戒断(COWS≥13)者7例(7.0% [95%CI, 2.9%-13.9%]),1小时内出现 precipitated withdrawal 者2例(2.0% [95%CI, 0.2%-7.0%])。注射部位疼痛即刻中位数2.0分、4小时中位数0分。第7天73%患者参与阿片类物质使用障碍治疗,5例严重不良事件需住院、其中2例与药物相关。作者认为该制剂在COWS 4-7患者中可接受、耐受良好且安全,可能大幅增加接受丁丙诺啡的患者数。

要点

  • COWS 0-7的急诊OUD患者单次注射24 mg缓释7日丁丙诺啡(CAM2038)后,4小时内COWS升高≥5分者10.0%(95%CI 4.9%-17.6%)。
  • 4小时内转为COWS≥13者7.0%(95%CI 2.9%-13.9%);1小时内precipitated withdrawal 2.0%(95%CI 0.2%-7.0%)。
  • 4小时内precipitated withdrawal共7.0%(95%CI 2.9%-13.9%),COWS 4-7者3.2%(2/63) vs COWS 0-3者13.5%(5/37)。
  • 注射部位疼痛即刻中位数2.0分(范围0-10.0)、4小时中位数0分(范围0-10.0)。
  • 第7天73%患者参与OUD治疗;5例严重不良事件需住院,其中2例与药物相关。

适用人群与场景

  • 美国东北部、中大西洋和太平洋地区4个急诊科,年龄≥18岁、中度至重度阿片类物质使用障碍且COWS评分<8(极轻至轻度,评分范围0-7,评分越高戒断越重)的成人。
  • 排除标准包括尿检美沙酮阳性、妊娠、过量或需要住院者。

诊断标准与关键阈值

  • 临床阿片戒断量表(COWS)评分<8(极轻至轻度,评分范围0-7)。
  • 主要可行性终点:注射后4小时内COWS评分升高≥5分,或转为中度及以上戒断(COWS评分≥13),或注射后1小时内出现 precipitated withdrawal。

处置流程与药物剂量

  • 单次注射24 mg缓释7日丁丙诺啡(CAM2038),并转介持续阿片类物质使用障碍治疗。
  • 基线、注射后7天内每日电话随访、第7天面对面评估结局。

红旗征与不能漏的情况

  • 注射后1小时内出现 precipitated withdrawal。
  • 注射后4小时内COWS评分升高≥5分或转为COWS评分≥13(中度及以上戒断)。

研究设计与关键结果

  • 非随机试验,纳入100例成人(平均[SD]年龄36.5[8.7]岁;72%男性),招募时间2020年7月13日至2023年5月25日。
  • 4小时内COWS升高≥5分者10例(10.0% [95%CI, 4.9%-17.6%]);转为中度及以上戒断(COWS≥13)者7例(7.0% [95%CI, 2.9%-13.9%]);1小时内precipitated withdrawal 2例(2.0% [95%CI, 0.2%-7.0%])。
  • 4小时内precipitated withdrawal共7例(7.0% [95%CI, 2.9%-13.9%]),其中COWS 4-7者2/63(3.2%),COWS 0-3者5/37(13.5%)。
  • 注射部位疼痛评分(总分10,0无痛、10最痛)即刻中位数2.0(范围0-10.0),4小时中位数0(范围0-10.0)。
  • 在应答者中任一日无渴求感者29例(33%)至31例(43%),无阿片使用报告者59例(78%)至75例(85%);57例(60%)报告无阿片使用天数。
  • 改善隐私(62%)和不需每日用药(67%)被认为极其重要;第7天73例(73%)参与OUD治疗。
  • 5例严重不良事件需住院,其中2例与药物相关。

证据类型、等级与局限

  • 研究类型:非随机试验(可行性研究),样本量100例。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在COWS评分0-7(极轻至轻度戒断)的患者中,7日丁丙诺啡注射剂可接受、耐受良好且安全,尤其COWS 4-7者;该新制剂可能大幅增加接受丁丙诺啡的OUD患者数。
  • COWS 0-3者4小时内precipitated withdrawal发生率13.5%(5/37),高于COWS 4-7者的3.2%(2/63)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Buprenorphine is an effective yet underused treatment for opioid use disorder (OUD).

OBJECTIVE: To evaluate the feasibility (acceptability, tolerability, and safety) of 7-day injectable extended-release buprenorphine in patients with minimal to mild opioid withdrawal.

DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized trial comprising 4 emergency departments in the Northeast, mid-Atlantic, and Pacific geographic areas of the US included adults aged 18 years or older with moderate to severe OUD and Clinical Opiate Withdrawal Scale (COWS) scores less than 8 (minimal to mild), in which scores range from 0 to 7, with higher scores indicating increasing withdrawal. Exclusion criteria included methadone-positive urine, pregnancy, overdose, or required admission. Outcomes were assessed at baseline, daily for 7 days by telephone surveys, and in person at 7 days. Patient recruitment occurred between July 13, 2020, and May 25, 2023.

INTERVENTION: Injection of a 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038) and referral for ongoing OUD care.

MAIN OUTCOMES AND MEASURES: Primary feasibility outcomes included the number of patients who (1) experienced a 5-point or greater increase in the COWS score or (2) transitioned to moderate or greater withdrawal (COWS score ≥13) within 4 hours of extended-release buprenorphine or (3) experienced precipitated withdrawal within 1 hour of extended-release buprenorphine. Secondary outcomes included injection pain, satisfaction, craving, use of nonprescribed opioids, adverse events, and engagement in OUD treatment.

RESULTS: A total of 100 adult patients were enrolled (mean [SD] age, 36.5 [8.7] years; 72% male). Among the patients, 10 (10.0% [95% CI, 4.9%-17.6%]) experienced a 5-point or greater increase in COWS and 7 (7.0% [95% CI, 2.9%-13.9%]) transitioned to moderate or greater withdrawal within 4 hours, and 2 (2.0% [95% CI, 0.2%-7.0%]) experienced precipitated withdrawal within 1 hour of extended-release buprenorphine. A total of 7 patients (7.0% [95% CI, 2.9%-13.9%]) experienced precipitated withdrawal within 4 hours of extended-release buprenorphine, which included 2 of 63 (3.2%) with a COWS score of 4 to 7 and 5 of 37 (13.5%) with a COWS score of 0 to 3. Site pain scores (based on a total pain score of 10, in which 0 indicated no pain and 10 was the worst possible pain) after injection were low immediately (median, 2.0; range, 0-10.0) and after 4 hours (median, 0; range, 0-10.0). On any given day among those who responded, between 29 (33%) and 31 (43%) patients reported no cravings and between 59 (78%) and 75 (85%) reported no use of opioids; 57 patients (60%) reported no days of opioid use. Improving privacy (62%) and not requiring daily medication (67%) were deemed extremely important. Seventy-three patients (73%) were engaged in OUD treatment on day 7. Five serious adverse events occurred that required hospitalization, of which 2 were associated with medication.

CONCLUSIONS AND RELEVANCE: This nonrandomized trial of the feasibility of a 7-day buprenorphine injectable in patients with minimal to mild opioid withdrawal (COWS scores, 0-7) found the formulation to be acceptable, well tolerated, and safe in those with COWS scores of 4 to 7. This new medication formulation could substantially increase the number of patients with OUD receiving buprenorphine.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04225598.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. D'Onofrio G, Herring AA, Perrone J, et al. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024. PMID: 38976265. doi:10.1001/jamanetworkopen.2024.20702

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。